| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 26 | 2024 | 236 | 4.550 |
Why?
|
| Lung Neoplasms | 29 | 2024 | 543 | 4.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2021 | 232 | 1.520 |
Why?
|
| Antineoplastic Agents | 6 | 2022 | 194 | 1.090 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2023 | 162 | 1.030 |
Why?
|
| Chemoradiotherapy | 11 | 2023 | 57 | 0.880 |
Why?
|
| Quinazolines | 3 | 2012 | 17 | 0.820 |
Why?
|
| Esophageal Neoplasms | 2 | 2019 | 49 | 0.690 |
Why?
|
| Neoplasm Staging | 18 | 2024 | 355 | 0.680 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2018 | 11 | 0.650 |
Why?
|
| Head and Neck Neoplasms | 4 | 2023 | 136 | 0.630 |
Why?
|
| Esophagectomy | 1 | 2019 | 22 | 0.630 |
Why?
|
| Sarcopenia | 1 | 2019 | 26 | 0.610 |
Why?
|
| Aged | 25 | 2024 | 7448 | 0.590 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 65 | 0.560 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 60 | 0.550 |
Why?
|
| Radiotherapy, Conformal | 2 | 2014 | 18 | 0.540 |
Why?
|
| ErbB Receptors | 6 | 2023 | 53 | 0.530 |
Why?
|
| Humans | 42 | 2024 | 23152 | 0.530 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2019 | 19 | 0.520 |
Why?
|
| Pneumonectomy | 2 | 2015 | 76 | 0.520 |
Why?
|
| Neoadjuvant Therapy | 4 | 2016 | 62 | 0.510 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 331 | 0.510 |
Why?
|
| Immunotherapy | 3 | 2021 | 50 | 0.510 |
Why?
|
| Female | 29 | 2024 | 13031 | 0.500 |
Why?
|
| Biomarkers | 1 | 2018 | 478 | 0.480 |
Why?
|
| Male | 27 | 2024 | 12524 | 0.470 |
Why?
|
| Gene Dosage | 2 | 2012 | 17 | 0.470 |
Why?
|
| Prognosis | 10 | 2022 | 722 | 0.460 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2011 | 7 | 0.450 |
Why?
|
| Social Class | 1 | 2014 | 53 | 0.430 |
Why?
|
| Postoperative Complications | 1 | 2019 | 817 | 0.410 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2019 | 84 | 0.400 |
Why?
|
| Middle Aged | 20 | 2024 | 7997 | 0.390 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 21 | 0.380 |
Why?
|
| Survival Analysis | 8 | 2021 | 234 | 0.360 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 44 | 0.360 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 193 | 0.350 |
Why?
|
| Retrospective Studies | 14 | 2023 | 3036 | 0.350 |
Why?
|
| Treatment Outcome | 16 | 2021 | 3038 | 0.340 |
Why?
|
| Cyclooxygenase 2 | 2 | 2014 | 29 | 0.320 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 15 | 0.320 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 200 | 0.320 |
Why?
|
| Neoplasms | 2 | 2022 | 215 | 0.290 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 19 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 160 | 0.280 |
Why?
|
| Adenocarcinoma | 3 | 2018 | 134 | 0.270 |
Why?
|
| Survival Rate | 6 | 2018 | 307 | 0.260 |
Why?
|
| Mutation | 4 | 2023 | 327 | 0.250 |
Why?
|
| Combined Modality Therapy | 7 | 2019 | 293 | 0.230 |
Why?
|
| Induction Chemotherapy | 2 | 2016 | 13 | 0.230 |
Why?
|
| Body Composition | 1 | 2024 | 63 | 0.220 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2014 | 31 | 0.210 |
Why?
|
| Disease-Free Survival | 6 | 2018 | 160 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 53 | 0.210 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 28 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 30 | 0.200 |
Why?
|
| Primary Dysautonomias | 1 | 2023 | 2 | 0.200 |
Why?
|
| Mouth Neoplasms | 1 | 2023 | 19 | 0.200 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2021 | 17 | 0.190 |
Why?
|
| United States | 4 | 2019 | 1794 | 0.190 |
Why?
|
| Maytansine | 1 | 2022 | 2 | 0.190 |
Why?
|
| Immunoconjugates | 1 | 2022 | 7 | 0.190 |
Why?
|
| Nose Neoplasms | 1 | 2022 | 35 | 0.190 |
Why?
|
| Thoracic Neoplasms | 1 | 2022 | 9 | 0.190 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 59 | 0.190 |
Why?
|
| Databases, Factual | 4 | 2019 | 304 | 0.180 |
Why?
|
| Body Weight | 2 | 2024 | 128 | 0.180 |
Why?
|
| Weight Gain | 2 | 2012 | 58 | 0.180 |
Why?
|
| Carcinoma, Large Cell | 2 | 2018 | 12 | 0.170 |
Why?
|
| Quality of Life | 3 | 2023 | 548 | 0.170 |
Why?
|
| Autoantibodies | 1 | 2021 | 62 | 0.170 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2015 | 15 | 0.170 |
Why?
|
| B7-H1 Antigen | 2 | 2021 | 7 | 0.170 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 9 | 0.160 |
Why?
|
| Injections, Intralesional | 1 | 2019 | 28 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 1457 | 0.160 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 335 | 0.160 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 6 | 0.160 |
Why?
|
| Papillomavirus Infections | 2 | 2016 | 19 | 0.150 |
Why?
|
| Taxoids | 2 | 2015 | 11 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2019 | 1445 | 0.150 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 62 | 0.150 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 18 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2018 | 7 | 0.150 |
Why?
|
| Registries | 2 | 2022 | 168 | 0.140 |
Why?
|
| Adult | 7 | 2019 | 7038 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 397 | 0.140 |
Why?
|
| Proteomics | 1 | 2018 | 58 | 0.140 |
Why?
|
| Palliative Care | 2 | 2015 | 106 | 0.130 |
Why?
|
| Leukocyte Count | 1 | 2017 | 56 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2017 | 50 | 0.130 |
Why?
|
| Neutrophils | 1 | 2017 | 93 | 0.130 |
Why?
|
| Age Factors | 2 | 2018 | 635 | 0.130 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 3711 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 366 | 0.120 |
Why?
|
| Robotic Surgical Procedures | 1 | 2015 | 26 | 0.120 |
Why?
|
| Carcinoma | 2 | 2015 | 66 | 0.120 |
Why?
|
| Prostaglandins | 1 | 2014 | 3 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2015 | 112 | 0.110 |
Why?
|
| Actuarial Analysis | 1 | 2014 | 8 | 0.110 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 6 | 0.110 |
Why?
|
| Academies and Institutes | 1 | 2014 | 11 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 114 | 0.110 |
Why?
|
| Propensity Score | 1 | 2014 | 35 | 0.110 |
Why?
|
| Parotid Gland | 1 | 2014 | 17 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 86 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2018 | 1507 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 102 | 0.100 |
Why?
|
| Logistic Models | 1 | 2014 | 341 | 0.100 |
Why?
|
| Sulfonamides | 2 | 2014 | 44 | 0.100 |
Why?
|
| Prevalence | 1 | 2014 | 390 | 0.100 |
Why?
|
| Patient Selection | 3 | 2021 | 169 | 0.090 |
Why?
|
| Papillomaviridae | 3 | 2016 | 17 | 0.090 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 10 | 0.090 |
Why?
|
| Therapies, Investigational | 1 | 2011 | 5 | 0.090 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 17 | 0.090 |
Why?
|
| Xanthine Dehydrogenase | 1 | 2010 | 6 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 10 | 0.080 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 15 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 26 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2012 | 398 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 13 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 20 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2009 | 31 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2010 | 128 | 0.080 |
Why?
|
| Peptic Ulcer | 1 | 2008 | 4 | 0.070 |
Why?
|
| Celecoxib | 1 | 2008 | 6 | 0.070 |
Why?
|
| In Situ Hybridization | 1 | 2008 | 48 | 0.070 |
Why?
|
| Length of Stay | 2 | 2023 | 300 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2008 | 59 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 419 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 600 | 0.060 |
Why?
|
| Pemetrexed | 2 | 2015 | 4 | 0.060 |
Why?
|
| Lymph Nodes | 2 | 2016 | 70 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 153 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2018 | 29 | 0.060 |
Why?
|
| Lung | 2 | 2019 | 150 | 0.060 |
Why?
|
| Radiotherapy Dosage | 2 | 2015 | 94 | 0.060 |
Why?
|
| Etoposide | 2 | 2015 | 25 | 0.050 |
Why?
|
| Carboplatin | 2 | 2015 | 24 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2015 | 49 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2023 | 16 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2019 | 525 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 30 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2023 | 27 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2015 | 230 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 30 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2024 | 396 | 0.050 |
Why?
|
| Cetuximab | 1 | 2021 | 5 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 92 | 0.050 |
Why?
|
| Phototherapy | 1 | 2021 | 27 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2021 | 41 | 0.040 |
Why?
|
| Observer Variation | 1 | 2021 | 87 | 0.040 |
Why?
|
| Squalene | 1 | 2019 | 2 | 0.040 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2019 | 4 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2019 | 13 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2019 | 18 | 0.040 |
Why?
|
| Seasons | 1 | 2019 | 18 | 0.040 |
Why?
|
| Vaccination | 1 | 2019 | 25 | 0.040 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2019 | 18 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 33 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2019 | 33 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 50 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2019 | 42 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 9 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 66 | 0.040 |
Why?
|
| Skin | 1 | 2019 | 118 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 44 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 165 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 109 | 0.040 |
Why?
|
| Animals | 2 | 2019 | 3253 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 355 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 90 | 0.040 |
Why?
|
| Radiation Pneumonitis | 1 | 2015 | 4 | 0.030 |
Why?
|
| Hemoptysis | 1 | 2015 | 6 | 0.030 |
Why?
|
| Esophagitis | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cough | 1 | 2015 | 9 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 1233 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 30 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 18 | 0.030 |
Why?
|
| Chest Pain | 1 | 2015 | 17 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 50 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2015 | 25 | 0.030 |
Why?
|
| Dyspnea | 1 | 2015 | 35 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 110 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 5 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 24 | 0.030 |
Why?
|
| Guanine | 1 | 2014 | 4 | 0.030 |
Why?
|
| Glutamates | 1 | 2014 | 7 | 0.030 |
Why?
|
| Pyrroles | 1 | 2014 | 23 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2015 | 72 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 449 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2015 | 117 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2014 | 380 | 0.030 |
Why?
|
| Diet | 1 | 2015 | 182 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 48 | 0.030 |
Why?
|
| Adolescent | 1 | 2018 | 1897 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 1713 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 427 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 23 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2011 | 41 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2011 | 42 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2010 | 21 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 84 | 0.020 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2010 | 4 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 4 | 0.020 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2010 | 4 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2010 | 8 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 29 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 36 | 0.020 |
Why?
|
| Cadherins | 1 | 2010 | 30 | 0.020 |
Why?
|
| CpG Islands | 1 | 2010 | 42 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 49 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 48 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 51 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 84 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 519 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 191 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 167 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 1944 | 0.020 |
Why?
|
| Smoking | 1 | 2010 | 160 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2010 | 501 | 0.020 |
Why?
|